233 related articles for article (PubMed ID: 9798695)
1. Serum cytokine levels after HLA-identical bone marrow transplantation.
Liem LM; van Houwelingen HC; Goulmy E
Transplantation; 1998 Oct; 66(7):863-71. PubMed ID: 9798695
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease.
Kobayashi S; Imamura M; Hashino S; Tanaka J; Asaka M
Leuk Lymphoma; 1997 Dec; 28(1-2):159-69. PubMed ID: 9498715
[TBL] [Abstract][Full Text] [Related]
3. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
4. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
Toren A; Novick D; Or R; Ackerstein A; Slavin S; Nagler A
Transplantation; 1996 Jul; 62(1):138-42. PubMed ID: 8693533
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias.
Engelhard D; Nagler A; Singer R; Barak V
Leuk Lymphoma; 1994 Jan; 12(3-4):273-80. PubMed ID: 8167558
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease.
Kami M; Matsumura T; Tanaka Y; Mikami Y; Miyakoshi S; Ueyama J; Morinaga S; Mori S; Machida U; Kanda Y; Chiba S; Sakamaki H; Hirai H; Muto Y
Leuk Lymphoma; 2000 Aug; 38(5-6):533-40. PubMed ID: 10953974
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation.
Nagler A; Bishara A; Brautbar C; Barak V
Cytokines Cell Mol Ther; 1998 Sep; 4(3):161-7. PubMed ID: 9825841
[TBL] [Abstract][Full Text] [Related]
10. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.
Schwaighofer H; Oberhuber G; Hebart H; Einsele H; Herold M; Nachbaur D; Eibl B; Tilg H; Kropshofer G; Ferrara JL; Niederwieser D
Transplantation; 1997 Jan; 63(1):52-6. PubMed ID: 9000660
[TBL] [Abstract][Full Text] [Related]
11. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
Remberger M; Ringdén O
Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
[TBL] [Abstract][Full Text] [Related]
12. Cell surface markers and circulating cytokines in graft versus host disease.
Chang DM; Wang CJ; Kuo SY; Lai JH
Immunol Invest; 1999 Jan; 28(1):77-86. PubMed ID: 10073684
[TBL] [Abstract][Full Text] [Related]
13. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.
Imamura M; Hashino S; Kobayashi H; Kubayashi S; Hirano S; Minagawa T; Tanaka J; Fujii Y; Kobayashi M; Kasai M
Bone Marrow Transplant; 1994 Jun; 13(6):745-51. PubMed ID: 7920309
[TBL] [Abstract][Full Text] [Related]
14. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
[TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.
Grimm J; Zeller W; Zander AR
Bone Marrow Transplant; 1998 Jan; 21(1):29-32. PubMed ID: 9486491
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host disease.
Liem LM; Koelman CA; Doxiadis II; van Houwelingen JC; Goulmy E; Claas FH
Bone Marrow Transplant; 1997 Aug; 20(3):227-34. PubMed ID: 9257891
[TBL] [Abstract][Full Text] [Related]
17. Predicting graft-versus-host disease in HLA-identical bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant model.
Dickinson AM; Sviland L; Wang XN; Jackson G; Taylor PR; Dunn A; Proctor SJ
Transplantation; 1998 Oct; 66(7):857-63. PubMed ID: 9798694
[TBL] [Abstract][Full Text] [Related]
18. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning.
Kaida K; Ikegame K; Ikemoto J; Murata R; Irie R; Yoshihara S; Ishii S; Okada M; Inoue T; Tamaki H; Soma T; Fujimori Y; Kai S; Ogawa H
Int J Hematol; 2014 Apr; 99(4):463-70. PubMed ID: 24599414
[TBL] [Abstract][Full Text] [Related]
20. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
